Novo Holdings A/S — 13F Holdings & Portfolio
CIK 1388325 · latest 13F-HR filed 2026-08-14
Novo Holdings A/S manages $1.72B in 13F-reported U.S. long-equity assets across 25 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are EWTX (12.62%), ASML (10.97%), COAG (8.92%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 6 new positions, exited 3, added to 8, and trimmed 6.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
HELLERUP 2900
$1.72B
Long-equity book
25
Distinct positions
2026-06-30
Filed 2026-08-14
+6 / −3 / ↑8 / ↓6
vs 2026-03-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- ASML HOLDING N V$63.5M +50.6%
- MAPLIGHT THERAPEUTICS INC$57.2M +76.3%
- EDGEWISE THERAPEUTICS INC$48.8M +29.0%
- MIRUM PHARMACEUTICALS INC$9.3M +7.6%
- 4D MOLECULAR THERAPEUTICS IN$9.2M +27.1%
Top Trims
- SALESFORCE INC-$11.8M -16.1%
- ALIBABA GROUP HLDG LTD-$7.6M -23.5%
- CRINETICS PHARMACEUTICALS IN-$6.9M -12.3%
- VAXCYTE INC-$3.5M -6.9%
- BRIDGEBIO ONCOLOGY THERAPEUT-$2.4M -12.4%
New Positions
- HEMAB THERAPEUTICS HLDGS INC$153.6M
- AVALYN PHARMACEUTICALS INC$127.8M
- FLOOR & DECOR HLDGS INC$47.3M
- ALUMIS INC$31.0M
- DYNE THERAPEUTICS INC$21.3M
Exited Positions
- APOGEE THERAPEUTICS INC$37.9M
- BIOMARIN PHARMACEUTICAL INC$37.3M
- VALNEVA SE$6.6M
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | EDGEWISE THERAPEUTICS INC | EWTX | 28036F105 | $217.4M | 12.62% | 5,350,000 | SH |
| 2 | ASML HOLDING N V | ASML | N07059210 | $188.9M | 10.97% | 94,946 | SH |
| 3 | HEMAB THERAPEUTICS HLDGS INC | COAG | 423494103 | $153.6M | 8.92% | 4,180,550 | SH |
| 4 | BROOKFIELD CORP | BN | 11271J107 | $149.5M | 8.68% | 3,496,245 | SH |
| 5 | MAPLIGHT THERAPEUTICS INC | MPLT | 56565P103 | $132.1M | 7.67% | 3,686,622 | SH |
| 6 | MIRUM PHARMACEUTICALS INC | MIRM | 604749101 | $131.7M | 7.65% | 1,125,000 | SH |
| 7 | AVALYN PHARMACEUTICALS INC | AVLN | 05348Y105 | $127.8M | 7.42% | 3,883,289 | SH |
| 8 | SALESFORCE INC | CRM | 79466L302 | $61.6M | 3.58% | 393,187 | SH |
| 9 | ARRIVENT BIOPHARMA INC | AVBP | 04272N102 | $52.1M | 3.03% | 1,500,000 | SH |
| 10 | ENLIVEN THERAPEUTICS INC | ELVN | 29337E102 | $50.8M | 2.95% | 1,000,000 | SH |
| 11 | CRINETICS PHARMACEUTICALS IN | CRNX | 22663K107 | $49.4M | 2.87% | 1,320,000 | SH |
| 12 | PHARVARIS N V | PHVS | N69605108 | $48.4M | 2.81% | 1,400,000 | SH |
| 13 | FLOOR & DECOR HLDGS INC | FND | 339750101 | $47.3M | 2.75% | 797,000 | SH |
| 14 | VAXCYTE INC | PCVX | 92243G108 | $46.5M | 2.70% | 800,000 | SH |
| 15 | 4D MOLECULAR THERAPEUTICS IN | FDMT | 35104E100 | $43.2M | 2.51% | 3,249,178 | SH |
| 16 | VIRIDIAN THERAPEUTICS INC | VRDN | 92790C104 | $39.2M | 2.28% | 2,135,000 | SH |
| 17 | CELLDEX THERAPEUTICS INC NEW | CLDX | 15117B202 | $38.1M | 2.21% | 1,025,000 | SH |
| 18 | ALUMIS INC | ALMS | 022307102 | $31.0M | 1.80% | 1,100,000 | SH |
| 19 | XENON PHARMACEUTICALS INC | XENE | 98420N105 | $29.3M | 1.70% | 485,438 | SH |
| 20 | ALIBABA GROUP HLDG LTD | BABA | 01609W102 | $24.7M | 1.43% | 257,327 | SH |
| 21 | DYNE THERAPEUTICS INC | DYN | 26818M108 | $21.3M | 1.24% | 960,394 | SH |
| 22 | BRIDGEBIO ONCOLOGY THERAPEUT | BBOT | 107924102 | $17.1M | 1.00% | 2,250,000 | SH |
| 23 | INSMED INC | INSM | 457669307 | $12.9M | 0.75% | 120,723 | SH |
| 24 | MARQETA INC | MQ | 57142B104 | $7.2M | 0.42% | 441,558 | SH |
| 25 | LANZATECH GLOBAL INC | LNZA | 51655R200 | $1.1M | 0.06% | 158,148 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-14 | $1.72B | 25 | 0001388325-26-000042 |
| 2026-03-31 | 2026-05-15 | $1.23B | 22 | 0001388325-26-000026 |
| 2025-12-31 | 2026-02-17 | $1.29B | 24 | 0001388325-26-000007 |
| 2025-09-30 | 2025-11-14 | $1.55B | 27 | 0001388325-25-000025 |